| Bioactivity | Daxdilimab is an anti-ILT7 monoclonal antibody, ILT7 is a cell surface molecule specific to the pDC type of dendritic cells. Daxdilimab can be used in acute lung injury (ALI) in patients with COVID-19 infection research[1][2]. |
| Name | Daxdilimab |
| CAS | 2245966-28-1 |
| Appearance | Liquid |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Patel S, et al. Recent updates in the clinical trials of therapeutic monoclonal antibodies targeting cytokine storm for the management of COVID-19. Heliyon. 2021 Feb;7(2):e06158. [2]. Retamozo S, et al. An update of targeted therapeutic options for primary Sjögren syndrome: current status and future development. Expert Opin Pharmacother. 2021 Dec;22(17):2359-2371. |